Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torben Bjerregaard Larsen

Showing results (31-40 of 185) with videos related to

Pageof 19
Sort By:
Journal of the American College of Cardiology|January 1, 2013
Reply: To PMID 22575324Gregory Y H Lip, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Journal of the American College of Cardiology|May 12, 2012
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillationGregory Y H Lip, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Thrombosis Research|January 22, 2014
Improvement of anticoagulant treatment using a dynamic decision support algorithm: a Danish Cohort studyPeter Brønnum Nielsen, Søren Lundbye-Christensen, Lars Hvilsted Rasmussen, et al.
Thrombosis and Haemostasis|July 31, 2015
Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapyGregory Y H Lip, Flemming Skjøth, Peter B Nielsen, et al.
Thrombosis and Haemostasis|March 1, 2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysisFlemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen, et al.
JAMA Internal Medicine|February 28, 2017
Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial FibrillationPeter Brønnum Nielsen, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Expert Review of Cardiovascular Therapy|January 14, 2016
Self-managed oral anticoagulant therapy: a call for implementationThomas Decker Christensen, Erik Lerkevang Grove, Peter Brønnum Nielsen, et al.
Ugeskrift for Laeger|October 3, 2018
[Recurrence of venous thromboembolism]Jørn Dalsgaard Nielsen, Erik Lerkevang Grove, Torben Bjerregaard Larsen, et al.
Journal of the American College of Cardiology|March 16, 2015
Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc scoreGregory Y H Lip, Flemming Skjøth, Lars Hvilsted Rasmussen, et al.
Stroke|February 18, 2016
Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry StudyAnne Sig Vestergaard, Flemming Skjøth, Gregory Y H Lip, et al.
Pageof 19

Showing results (31-40 of 185) with videos related to

Sort By:
Pageof 19
Journal of the American College of Cardiology|January 1, 2013
Reply: To PMID 22575324Gregory Y H Lip, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Journal of the American College of Cardiology|May 12, 2012
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillationGregory Y H Lip, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Thrombosis Research|January 22, 2014
Improvement of anticoagulant treatment using a dynamic decision support algorithm: a Danish Cohort studyPeter Brønnum Nielsen, Søren Lundbye-Christensen, Lars Hvilsted Rasmussen, et al.
Thrombosis and Haemostasis|July 31, 2015
Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapyGregory Y H Lip, Flemming Skjøth, Peter B Nielsen, et al.
Thrombosis and Haemostasis|March 1, 2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysisFlemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen, et al.
JAMA Internal Medicine|February 28, 2017
Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial FibrillationPeter Brønnum Nielsen, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Expert Review of Cardiovascular Therapy|January 14, 2016
Self-managed oral anticoagulant therapy: a call for implementationThomas Decker Christensen, Erik Lerkevang Grove, Peter Brønnum Nielsen, et al.
Ugeskrift for Laeger|October 3, 2018
[Recurrence of venous thromboembolism]Jørn Dalsgaard Nielsen, Erik Lerkevang Grove, Torben Bjerregaard Larsen, et al.
Journal of the American College of Cardiology|March 16, 2015
Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc scoreGregory Y H Lip, Flemming Skjøth, Lars Hvilsted Rasmussen, et al.
Stroke|February 18, 2016
Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry StudyAnne Sig Vestergaard, Flemming Skjøth, Gregory Y H Lip, et al.
Pageof 19